The cerebrospinal fluid (CSF) of 22 consecutive untreated children with acute lymphocytic leukemia who entered total study VII from September to December 1971 at St. Jude Children’s Research Hospital was examined. Four patients had periodic acid-Schiff (PAS)-positive, Sudan black B- and peroxidase-negative lymphoblasts in the CSF at diagnosis. Two of the 4 developed meningeal leukemia 3 and 5 months following diagnosis. None revealed pleocytosis and/or detectable atypical cells on a Wright-stained smear of CSF sediment at diagnosis. Two patients had no more detectable PAS-positive lymphoblasts after ‘prophylactic’ central nervous system (CNS) radiotherapy. They are in continuous complete remission for 9 and 10 months. The recognition of a small number of CSF-abnormal cells with PAS reaction and the differentiation of blasts from inflammatory cells may allow an earlier diagnosis and treatment of CNS involvement in childhood acute lymphocytic leukemia.

Keywords:
Acute lymphocytic leukemia, Childhood leukemia, Meningeal leukemia, PAS reaction
This content is only available via PDF.
© 1973 S. Karger AG, Basel
1973
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.